Priority Review Granted for Drug Targeting Advanced EGFR-Mutated NSCLC
The treatment, designed for patients with advanced EGFR-mutated NSCLC resistant to prior therapies, could offer a new option pending FDA approval.
The treatment, designed for patients with advanced EGFR-mutated NSCLC resistant to prior therapies, could offer a new option pending FDA approval.
The treatment, designed for patients with advanced EGFR-mutated NSCLC resistant to prior therapies, could offer a new option pending FDA approval.
Read MoreDaiichi Sankyo has issued a voluntary recall for two measles vaccines manufactured by its group company, Kitasato Daiichi Sankyo, according to a company news announcement.
Read MoreThe European Commission has approved edoxaban (Lixiana, Daiichi Sankyo) for high-risk patients with nonvalvular atrial fibrillation (AF) and for the treatment and prevention of DVT and PE.
Read More